Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058681
Filing Date
2025-04-25
Accepted
2025-04-25 16:00:15
Documents
21
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A cue-20250425.htm   iXBRL DEF 14A 1447383
2 GRAPHIC img78869026_0.jpg GRAPHIC 31500
3 GRAPHIC img78869026_1.jpg GRAPHIC 31500
4 GRAPHIC img78869026_2.jpg GRAPHIC 6940
5 GRAPHIC img78869026_3.jpg GRAPHIC 87207
6 GRAPHIC img78869026_4.jpg GRAPHIC 81925
7 GRAPHIC img78869026_5.jpg GRAPHIC 163148
8 GRAPHIC img78869026_6.jpg GRAPHIC 241112
9 GRAPHIC img78869026_7.jpg GRAPHIC 69651
  Complete submission text file 0000950170-25-058681.txt   4090615

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cue-20250425.xsd EX-101.SCH 13696
23 EXTRACTED XBRL INSTANCE DOCUMENT cue-20250425_htm.xml XML 256207
Mailing Address 40 GUEST STREET BOSTON MA 02135
Business Address 40 GUEST STREET BOSTON MA 02135 617-949-2680
Cue Biopharma, Inc. (Filer) CIK: 0001645460 (see all company filings)

EIN.: 473324577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38327 | Film No.: 25873611
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)